Abstract
The radiobiology of radioimmunotherapy is an important determinant of both the toxicity and the efficacy associated with the treatment of B-cell non-Hodgkin's lymphoma with radiolabeled anti-CD20 monoclonal antibodies. The properties of the target, CD20, and the mechanisms of action of both the monoclonal antibodies and the associated exponentially decreasing low-dose-rate radiotherapy are described. The radiation dose and dose-rate effects are discussed and related to both the tumor responses and normal organ toxicity. Finally, the use of either unlabeled or radiolabeled anti-CD20 monoclonal antibodies as a component of combined modality therapy (including the sequential or concurrent use of sensitizers) and future directions of the field are discussed.
Original language | English (US) |
---|---|
Pages (from-to) | 1274-1287 |
Number of pages | 14 |
Journal | International Journal of Radiation Oncology Biology Physics |
Volume | 59 |
Issue number | 5 |
DOIs | |
State | Published - Aug 1 2004 |
Externally published | Yes |
Keywords
- B-cell non-Hodgkin's lymphoma
- Lymphoma
- Radiobiology
- Radioimmunotherapy
- Radiolabeled monoclonal antibody
ASJC Scopus subject areas
- Radiation
- Oncology
- Radiology Nuclear Medicine and imaging
- Cancer Research